Average Insider

Where insiders trade, we follow

$EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Healthcare
Sector
Biotechnology
Industry
Kevin Koch
CEO
117
Employees
$44.17
Current Price
$2.90B
Market Cap
52W Low$13.53
Current$44.1787.9% above low, 12.1% below high
52W High$48.40

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells519$1,899,034.4043,429
1 monthBuys00--All Sells
Sells519$1,899,034.4043,429
2 monthsBuys00--All Sells
Sells521$9,780,436.38243,429
3 monthsBuys00--All Sells
Sells521$9,780,436.38243,429
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 1, 2026
Russell Alan J
Director
Sale69,648$39.41$2,744,751.07View Details
14 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.7.3